Gemphire Therapeutics Inc (GEMP) Stock Price & Overview

NASDAQ:GEMP

Current stock price

0.3
0 (-0.37%)
At close:
0.3
0 (0%)
After Hours:

The current stock price of GEMP is 0.3 null. Today GEMP is down by -0.37%. In the past month the price decreased by -16.43%. In the past year, price decreased by -64.07%.

GEMP Key Statistics

52-Week Range0.238 - 1.485
Current GEMP stock price positioned within its 52-week range.
1-Month Range0.238 - 0.3869
Current GEMP stock price positioned within its 1-month range.
Market Cap
4.462M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.16
Dividend Yield
N/A

GEMP Stock Performance

Today
-0.37%
1 Week
N/A
1 Month
-16.43%
3 Months
-14.29%
Longer-term
6 Months -60.53%
1 Year -64.07%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

GEMP Stock Chart

Gemphire Therapeutics Inc / GEMP Daily stock chart

GEMP Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to GEMP. When comparing the yearly performance of all stocks, GEMP is a bad performer in the overall market: 96.12% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
GEMP Full Technical Analysis Report

GEMP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GEMP. GEMP may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GEMP Full Fundamental Analysis Report

GEMP Earnings

Next Earnings DateN/A
Last Earnings DateN/A
GEMP Earnings History

GEMP Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next Y-46.2%
Revenue Next YearN/A
GEMP Forecast & Estimates

GEMP Financial Highlights

Over the last trailing twelve months GEMP reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 53.6% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-13.81M
Industry RankSector Rank
PM (TTM) N/A
ROA -674.17%
ROE N/A
Debt/Equity -6.24
Chartmill High Growth Momentum
EPS Q2Q%57.45%
Sales Q2Q%N/A
EPS 1Y (TTM)53.6%
Revenue 1Y (TTM)N/A
GEMP financials

GEMP Ownership

Ownership
Inst Owners17.53%
Shares14.87M
Float10.80M
Ins Owners25.01%
Short Float %N/A
Short RatioN/A
GEMP Ownership

About GEMP

Company Profile

Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.

Company Info

Gemphire Therapeutics Inc

17199 N. LAUREL PARK DRIVE SUITE 401

LIVONIA MI 48152

CEO: Steven Gullans

Phone: 734-245-1700

Gemphire Therapeutics Inc / GEMP FAQ

What does GEMP do?

Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.


What is the current price of GEMP stock?

The current stock price of GEMP is 0.3 null. The price decreased by -0.37% in the last trading session.


What is the dividend status of Gemphire Therapeutics Inc?

GEMP does not pay a dividend.


What is the ChartMill rating of Gemphire Therapeutics Inc stock?

GEMP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.